No need to login to view prices!
|Create new account|
Due to technical maintenance the webshop is closed until January 3rd, 2022. We wish you a successful 2022!
NOVEMBER 3, 2015, NATIONAL HARBOR, MD (US BUSINESS WIRE) Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, announced today the release of 6 new monoclonal antibodies (mAb) for tumor immunology research. This announcement was made at the 30th annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD November 4-8th, 2015.
CST has released PD-L2 (D7U8C) XP® Rabbit mAb #82723, PD-L1 (Extracellular Domain Specific) (E1J2J) Rabbit mAb #15165, PD-L1 (405.9A11) Mouse mAb #29122, PD-1 (EH33) Mouse mAb #43248, TIM-3 (D5D5R) XP® Rabbit mAb #45208, and IDO (D5J4E) Rabbit mAb #86630. Each of these antibodies has been validated according to CST’s stringent standards to recognize their specific immune regulatory target by immunohistochemistry.
These antibodies add to a growing portfolio of tumor immunology products that includes the first to market, human-specific, IHC-approved VISTA (D1L2G™) XP® Rabbit mAb #64953, as well as PD-L1 (E1L3N®) XP® Rabbit mAb #13684, PD-1 (D3W4U) Rabbit mAb #15121, CTLA-4 (D4E9I) Rabbit mAb #15119, OX40 (D1S6L) Rabbit mAb #15123, B7-H3 (D9M2L) XP® Rabbit mAb #14058, and B7-H4 (D1M8I) XP® Rabbit mAb #14572.
Today’s announcement follows the October 6th, 2015 announcement that CST’s best-in-class recombinant rabbit monoclonal antibodies, developed with their proprietary XMT® and NG-XMTTM technologies can now be manufactured according to FDA (Food and Drug Administration) GMP (Good Manufacturing Practices) requirements for Analyte Specific Reagents.
“The release of these products reflects our continued commitment to provide complete turnkey solutions to the tumor immunology community. Moreover, our ability to manufacture GMP-grade antibodies puts us in a position to support translational tumor immunology research, from project conception through to clinical application. This has the potential to facilitate translational assay development and simplify the bench to bedside transition,” said Michael J. Comb, CEO of CST.
XP®, XMT®, NG-XMTTM, D1L2G™, E1L3N®, Cell Signaling Technology®, and CST™ are trademarks of Cell Signaling Technology, Inc.